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We report the discovery of GATA2 as a new myelodysplastic syndrome (MDS)-acute myeloid leukemia (AML) predisposition gene. We found the same, previously unidentified heterozygous c.1061C>T (p.Thr354Met) missense mutation in the GATA2 transcription factor gene segregating with the multigenerational transmission of MDS-AML in three families and a GATA2 c.1063_1065delACA (p.Thr355del) mutation at an adjacent codon in a fourth MDS family. The resulting alterations reside within the second zinc finger of GATA2, which mediates DNA-binding and protein-protein interactions. We show differential effects of the mutations on the transactivation of target genes, cellular differentiation, apoptosis and global gene expression. Identification of such predisposing genes to familial forms of MDS and AML is critical for more effective diagnosis and prognosis, counseling, selection of related bone marrow transplant donors and development of therapies.
AML is the most common form of sporadic leukemia in adults 1 , and MDS is a clonal disorder of hematopoietic stem cells characterized by ineffective hematopoiesis with a tendency to progress to AML 2 . Although rare, dozens of families developing nonsyndromic forms of MDS and AML (that is, lacking other systemic manifestations) have been described. To date, only two MDS-AML predisposition genes have been recognized: RUNX1 (also known as AML1), encoding Runt-related transcription factor 1, and CEBPA, encoding CCAAT-enhancer binding protein α (reviewed in ref. 3 ).
Here we report a highly specific c.1061C>T (p.Thr354Met) heritable mutation in GATA2 co-segregating with early onset MDS-AML in three families. We also report a family with MDS with a 3-bp heritable deletion in GATA2 (resulting in p.Thr355del) which leads to the deletion of the second threonine in this sequence.
We determined the genomic DNA sequence of all RefSeq exons in 50 candidate genes ( Supplementary Table 1 ) from affected individuals representing five pedigrees with predisposition to MDS-AML who were prescreened for an absence of RUNX1 or CEBPA germline mutations. In three families, there was an identical heritable heterozygous variation in the transcription factor GATA2: c.1061C>T (p.Thr354Met) ( Fig. 1 and Supplementary  Fig. 1 ). In all three families p.Thr354Met segregated with disease, and no individuals had AML or MDS who did not also carry p.Thr354Met ( Fig. 1a and Supplementary Table 2 ). Some members in each family carried this variant but were unaffected (pedigree 1, individuals III-5 and III-8; pedigree 2, individual II-6; and pedigree 3, individual III-9).
We recently identified a fourth family in which a father and son, both affected by MDS, shared a heterozygous 3-bp heritable deletion in GATA2 (c.1063-1065delACA) resulting in p.Thr355del ( Fig. 1 and  Supplementary Fig. 1 ). Thr354 and Thr355 are the first two of five consecutive threonine residues in a highly conserved zinc finger 2 (ZF2) domain of GATA2 ( Supplementary Fig. 1b ), which is involved in DNA binding, heterodimerization and interaction with transcription factor PU. 1 (refs. 4,5) . PolyPhen-2 predicts that p.Thr354Met and p.Thr355del are likely to affect GATA2 function. Somatic variations in ZF2 of GATA2 have also been reported during chronic Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia l e t t e r s myeloid leukemia (CML) blast crisis (p.Leu359Val and p.Ala341_ Gly346del) 6 and recently, variations in ZF1 and ZF2 have been reported in AML-M5 (acute monocytic leukemia) (ref. 7) ( Fig. 1b,c) . Somatic mutations in the corresponding ZF2 of the related protein family member GATA3 are found in breast cancer 8 (Fig. 1c) .
High resolution melt analysis did not detect p.Thr354Met, p.Thr355del or other variants in exon 5 of GATA2 in 695 nonleukemic ethnically matched normal controls (comprising 1,390 chromosomes) ( Supplementary Fig. 2a and Supplementary Note). These variants were also not present in dbSNP132 or the 1000 Genomes Project database (July 2011; see URLs). Together with disease segregation data, this indicates that the GATA2 p.Thr354Met and p.Thr355del variants are the predisposing variations in these families with familial MDS-AML.
A distinguishing feature of the families with mutations in GATA2 was a lack of apparent 'accessory' phenotype inside or outside the hematopoietic system, which is akin to the thrombocytopenia and eosinophilia seen in AML-predisposed families with RUNX1 and CEBPA mutations, respectively 9, 10 . In all four families, the GATA2 mutations were associated with early onset MDS and/or AML, with highly penetrant autosomal dominant inheritance resulting in poor outcome unless successfully transplanted (for example, in pedigree 1, the age of death from AML ranged from 10-50 years, two individuals aged 58 and 62 years have the mutation but no disease, and all other siblings without the mutation are alive or have lived beyond 53 years of age) ( Supplementary Tables 2,3 and Supplementary Note). For pedigrees 1 and 3 (refs. 11,12) , the presentation varied, with some members showing protracted MDS and others showing acute onset; the French-American-British (FAB)-classified subtype and karyotypic features of AML varied. In pedigree 4, MDS was first diagnosed at age 13 in the son, who was treated with allogeneic bone marrow transplant at age 15; MDS was later diagnosed at age 53 in the father, who underwent allogeneic bone marrow transplantation.
We did not find heritable GATA2 coding variations in samples from another 8 families with multiple individuals with AML or in 27 families with multiple occurrences of lymphoid malignancies (11 with non-Hodgkin's lymphoma, 5 with Hodgkin's lymphoma, 3 with acute lymphoblastic leukemia, 7 with chronic lymphocytic leukemia and 1 with multiple myeloma). Also, we detected no GATA2 mutations in 15 hematopoietic cell lines ( Supplementary Table 4 ). We detected no Fig. 2c ), which was assessed as benign using PolyPhen-2 (see URLs). Together, this suggests that point mutations and small indels in the GATA2 coding sequence are not frequent in sporadic AML. Haplotype mapping using eight informative SNPs within and surrounding GATA2 showed that the c.1061C>T (p.Thr354Met) mutation segregated within two distinct haplotypes (Supplementary Table 5 ), indicating that this mutation has arisen at least twice among the three families in which it is found.
We generated complementary DNAs (cDNAs) for the p.Thr354Met and p.Thr355del mutant GATA2 proteins and the acquired CML blast crisis p.Leu359Val mutant 6 . Wild-type and mutant proteins were expressed at comparable levels when transiently expressed in HEK293 fibroblasts ( Fig. 2a) and when induced to express from a 4-hydroxytamoxifen (4HT)-responsive dual vector lentivirus system in stably transduced HL-60 promyelocytes ( Supplementary Fig. 3a) , and they appropriately localized to the nucleus ( Fig. 2b and Supplementary  Fig. 3b ). However, p.Thr354Met dramatically reduced the ability of GATA2 to bind its consensus WGATAR DNA motif, and p.Thr355del almost completely ablated DNA binding ( Fig. 2c and Supplementary Fig. 3c ).
Molecular modeling of GATA2 ZF2 ( Supplementary Fig. 4 and Supplementary Note) showed that the Thr354 residue does not contact DNA but rather makes polar contact with adjacent threonines and, through its amino group, with Cys349, which coordinates the zinc atom. Replacement of Thr354 with the bulky methionine moiety is predicted to alter the ZF2 structure by affecting zinc contacts. This may explain the reduced binding of p.Thr354Met to DNA ( Fig. 2c and Supplementary Fig. 3c ). In contrast, p.Thr355del shortens the conserved threonine string, likely affecting the orientation and position of Leu359, which directly contacts DNA. These observations likely explain the almost complete ablation of DNA binding.
Luciferase reporter assay experiments showed that GATA2 p.Thr354Met and p.Thr355del had reduced transactivation ability compared to wild-type on known GATA2 responsive enhancers (RUNX1 and CD34) and the LYL1 promoter ( Fig. 3a-c) . Experiments mixing wild-type with p.Thr354Met or p.Thr355del at a 1:1 ratio, mimicking heterozygosity, showed a dominant negative effect of the mutants over wild-type transcription activation in multiple systems (Fig. 3d,e and Supplementary Fig. 5) . Notably, wild-type and PU.1 transactivated the CSF1R (M-CSFR) promoter 2.4-fold and 2.5-fold, respectively, but together synergized to induce 18-fold transactivation ( Fig. 3e) . Whereas p.Leu359Val was similar to wild-type GATA2, p.Thr354Met and p.Thr355del resulted in dramatically reduced induction alone (1.5-fold and 0.9-fold, respectively) or with PU.1 (sevenfold and ninefold, respectively, compared to 18-fold with wild-type). p.Thr354Met and p.Thr355del also showed dominant negative activity, with transactivation by wild-type GATA2 reduced to ninefold and tenfold, respectively, in the presence of these mutants (which is only marginally above the sevenfold and ninefold transactivation, respectively, of the mutants alone). Hence, p.Thr354Met and p.Thr355del perturb the transactivation ability of GATA2, presumably by disrupting association with PU.1 or other interacting transcription factors, and are likely affect expression of downstream targets. Notably, whereas wild-type GATA2 had different responses in HEK293 cells compared to Cos-7 cells on the RUNX1 enhancer (activating versus repressing, respectively), p.Thr354Met showed loss-of-function activity in both cell types (Supplementary Fig. 6 ). Thus, on multiple GATA responsive elements, p.Thr354Met and p.Thr355del show lossof-function and also dominant negative effects.
HL-60 promyelocytes differentiate into granulocytes upon exposure to all-trans retinoic acid (ATRA), resulting in upregulation of CD11b, cessation of proliferation and subsequent promotion of apoptosis ( Fig. 4) . When expressed at equivalent levels under nondifferentiating conditions, unlike wild-type and p.Leu359Val, which inhibited proliferation and promoted apoptosis, p.Thr354Met and p.Thr355del acted as loss-of-function mutants (Fig. 4b,f,j) . However, in the presence of ATRA, p.Thr354Met alone enabled cell proliferation and/or survival (Fig. 4h) while simultaneously inhibiting differentiation and apoptosis (Fig. 4d,l and Supplementary Fig. 7) . p.Thr355del appeared to be a null mutant under these conditions.
In order to better understand the effects of the GATA2 mutants on gene expression, we performed microarray analysis to compare global gene expression in HL-60 cells expressing wild-type Figure 2 Subcellular localization and DNA binding properties of wild-type and mutant GATA2. We transiently transfected HEK293 cells with empty vector (EV) (pCMV-XL6 empty vector), wild-type (WT), p.Thr354Met, p.Thr355del or p.Leu359Val and harvested them after 24 h. (a) Protein blot analysis of GATA2 expression in nuclear lysates. We prepared the nuclear lysates and performed protein blots probing for GATA2. (b) We stained the cells for GATA2 (pink) and DAPI (blue). Scale bars, 10 µm. (c) Electromobility shift assay (EMSA) of wild-type and mutant GATA2. We prepared the nuclear lysates and bound them to the TCRδ enhancer (which contains the GATA binding site) oligonucleotide in the absence or presence of 200-fold unlabeled competitor oligonucleotide (D, human TCRδ enhancer; C, GATA consensus; G, granulocyte-macrophage colony stimulating factor (GM-CSF) promoter). We visualized the probes using chemiluminescence (top). GATA2 & NS corresponds to a band that contains both GATA2 and a non-specific protein. To visualize GATA2 alone, we performed an EMSA-protein blot probing with polyclonal α-GATA2 antibody (bottom), which shows the level of binding of wild-type and mutant GATA2. A neutralizing α-GATA2 antibody in the far right lane removed GATA2 but not the non-specific binding protein (top), and the specificity of GATA2 is confirmed below. l e t t e r s GATA2 and the three GATA2 mutants ( Supplementary Table 6 and Supplementary Fig. 8) . The data clearly showed that p.Thr355del and p.Thr354Met are almost total loss-of-function mutants (Supplementary Fig. 8 ). Note that p.Leu359Val shows gain of function (1,253 newly regulated genes compared to wild-type GATA2) and partial loss of function (457 genes no longer regulated) while retaining 786 genes commonly regulated. These results are consistent with electromobility shift assay (EMSA)-protein blot and transactivation assays. Further bioinformatics analysis indicated that MYC may be among key targets repressed by wild-type GATA2 but not by p.Thr354Met and p.Thr355del ( Supplementary Table 6 and Supplementary Note).
Notably, recurrent p.Leu359Val alteration in ZF2 of GATA2 was reported in 8 out of 85 individuals with CML blast crisis 6 , a disease often phenotypically indistinguishable from AML. As shown in Figure 1b and c, p.Thr354Met is situated between the deleted residues (p.Ala341_Gly346del), as is also observed in CML blast crisis, and the Leu359 residue. Leu359 contacts DNA at the guanine residue of the WGATAR consensus motif and, based on in vitro DNA binding and transactivation assays, p.Leu359Val has previously been reported to be a gain-of-function alteration, whereas p.Ala341_Gly346del appears to be a partial loss-of-function alteration. Met354 or deletion of Thr355 may affect overall ZF structure (Supplementary Fig. 4) , although we cannot exclude disrupted heterodimerization with GATA2's interacting partners ( Supplementary Table 7 ). We speculate that aberrant protein partnerships may explain dominant negative activity and adversely influence expression of genes critical to myelopoiesis.
The MDS-AML observed within these families is clinically heterogeneous and has a variety of somatic chromosomal abnormalities, including monosomy 7, trisomy 8 and trisomy 21 ( Supplementary  Table 2 ). As such, it is similar to familial MDS-AML with monosomy 7 (refs. 3, 13) . Moreover, we did not detect GATA2 mutations in 8 MDS-AML families in which RUNX1 and CEPBA mutations had been excluded and 27 families presenting with lymphoid malignancy. Alterations in ZF2 are likely to initiate an exclusively myeloid pathway of oncogenesis in which subsequent gene-specific somatically acquired mutations probably define the particular type of disease that ultimately arises.
The mechanism by which GATA2 p.Thr354Met and p.Thr355del alterations function is distinct to that generally described for RUNX1 and CEBPA, which commonly act as classical tumor suppressor genes with a wide range of mutations and requiring functional disruption of both alleles. Transcription factors are well characterized as targets of dominant negative or constitutively active mutations in cancer 14, 15 , with RUNX1 mutations leading to a spectrum of outcomes including AML and acute lymphoblastic leukemia, consistent with both tumor suppressor gene and dominant oncogene models 16, 17 . Although we have only been able to detect single allele GATA2 germline mutations in affected samples, we cannot rule out the possibility of acquired mutations in the 'normal' allele.
GATA2 is indispensable for hematopoiesis [17] [18] [19] . It associates with, regulates or is regulated by transcription factors implicated in myeloid malignancy (Supplementary Table 7) . Many of these interactions involve ZF2, in which the p.Thr354Met and p.Thr355del alterations reside, and it is likely that changes in the nature of these interactions play an important role in predisposition to MDS-AML. Indeed, our co-transfection studies are consistent with altered transactivation by p.Thr354Met and p.Thr355del with PU.1 (Fig. 3e) . p.Thr354Met, p.Thr355del or any other alterations in GATA2 were absent in our heterogeneous cohort of individuals with sporadic AML, although we cannot rule out possible mutations in samples with lowpercentage blasts. This is consistent with other recent studies, however, suggesting that somatic GATA2 alterations in both ZF1 and ZF2 could be acquired only in specific AML subtypes such as AML-M5 (refs. 7,20,21) . GATA2 is, however, overexpressed in many cases of sporadic MDS 22 and AML, particularly in FLT3-ITD positive AML 23 , suggesting that alterations to GATA2 expression, rather than direct mutation, may occur more commonly. Further, chromosomal aberrations at the 3q21 breakpoint cluster encompassing a presumptive GATA2 regulatory region resulted in upregulated GATA2 expression in MDS and AML 22,24-26 . Figure 3 p.Thr354Met and p.Thr355del cause altered transactivation through target GATA2 response elements. p.Thr354Met and p.Thr355del act as a loss-of-function alterations on GATA2 target promoter and enhancer elements. We cotransfected HEK293 cells with (i) GATA2-responsive CD34 (mut, CD34 enhancer with GATA binding sites mutated 32 ) (a) and RUNX1 (b) enhancer elements linked to a luciferase (LUC) reporter, and (ii) GATA2 (wild-type, p.Thr354Met, p.Thr355del or p.Leu359Val) expression constructs or pCMV6-XL6 empty vector (EV). Similarly, we cotransfected Cos-7 cells using LYL1 promoter luciferase as a reporter (c). After 20 h, we harvested the cells, performed luciferase assays and plotted them as fold change (mean ± s.e.m.) compared to the empty vector control. The pairwise comparisons are shown (*P < 0.05, for a,b and c n = 3). (d) p.Thr354Met and p.Thr355del act as dominant negative alterations over wild-type GATA2. We cotransfected HEK293 cells with CD34 enhancer-luciferase reporter and equivalent mole ratios of wild-type to p.Thr354Met or p.Thr355del. After 20 h, we harvested the cells and performed luciferase assays. The pairwise comparisons are shown (*P < 0.05, n = 3; NS, not significant). (e) p.Thr354Met has reduced ability to co-activate the CSF1R (M-CSFR) promoter with PU.1. We cotransfected Cos-7 cells with CSF1R promoter-luciferase reporter, PU.1 expression construct and wild-type, p.Thr354Met, p.Thr355del or p.Leu359Val expression constructs or empty vector. After 20 h, we performed luciferase assays and plotted them as fold change compared to empty vector. Pairwise comparisons are shown (*P < 0.05 compared to wild-type plus PU.1; **P < 0.05 compared to wild-type plus PU.1, but the results were not significant when compared to p.Thr354Met or p.Thr355del plus PU.1). In all comparisons, we used a Student's t-test. VOLUME 43 | NUMBER 10 | OCTOBER 2011 Nature GeNetics l e t t e r s
In addition, retroviral insertional mutagenesis in NUP98-HOXD13 mice, a model for human MDS-AML, identified Gata2 as a common insertion site in mice with induced AML, all of whom overexpressed Gata2 (ref. 27 ). Hence, accumulating evidence suggests that aberrant activation or overexpression of GATA2 contributes to AML. While this manuscript was under consideration, germline GATA2 mutations were reported (including those resulting in p.Thr354Met and other ZF2 and ZF1 alterations) in monocytopenia and mycobacterial infection (MonoMAC) syndrome 28 or dendritic cell, monocyte, B and natural killer lymphoid (DCML) deficiency 29 , autosomal dominant or sporadic syndromes associated with cytopenias, susceptibility to infections and MDS-AML. One family presented with MDS and lymphedema 28 31 .
In this study, we show that GATA2 is a new predisposition gene for familial MDS-AML and show functional changes caused by mutations within a highly conserved threonine repeat located in ZF2. Our findings highlight the power of approaches investigating familial predispositions to cancer and have implications for diagnostic genetic testing. The poor clinical outcome associated with these mutations suggests that an aggressive treatment strategy is appropriate for individuals carrying GATA2 mutations.
URLs. dbSNP132, http://www.ncbi.nlm.nih.gov/SNP/; 1000 Genomes Project, http://www.1000genomes.org/; PolyPhen-2, http://genetics. bwh.harvard.edu/pph2/.
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Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Accession codes. Affymetrix expression data are available from Gene Expression Omnibus under accession GSE29276. Human GATA2 cDNA sequence is available from GenBank under accession number NM_032638.4.
Note: Supplementary information is available on the Nature Genetics website.
ACKNoWLEDGMENTS
The authors would like to thank the families for their participation in our studies. Thanks also to J. Melo for provision of CML cell lines and R. Sharma for help with EMSA. Large-scale Sanger sequencing was performed by the Australian Genome Research Facility, which was established through the Commonwealth-funded Sequence analysis of candidate genes. To identify germline and somatic mutations in subjects with familial AML, a panel of 50 hematopoietic candidate genes, incorporating a total of 638 exons, was assembled ( Supplementary  Table 1 ). Primer design, PCR amplification and dideoxy sequencing of genomic DNA purified from lymphoblastoid cells of probands from seven MDS-AML pedigrees were performed by the Australian Genome Research Facility (AGRF). Sequences were aligned with NCBI RefSeq sequences using Mutation Surveyor (SoftGenetics), and variants were compared to the UCSC and NCBI SNP databases for novelty. Sequence changes were confirmed by resequencing in both directions. Primer sequences are available upon request. Screening of control and sporadic AML populations was performed using high resolution melt analysis ( Supplementary Table 8 and Supplementary Note).
Each single-stranded oligomer was labeled using a Biotin 3′ End DNA Labeling kit (Pierce) and annealed according to the manufacturer's protocol. EMSAs were performed using a modified protocol from a previous study 36 and visualized using a Chemiluminescent Nucleic Acid Detection Module (Pierce) according to the manufacturer's protocol. Double-stranded labeled probes (100 fmol) were incubated with 3 µg of nuclear extract for 20 min in 1× binding buffer containing 20 mM HEPES-KOH, pH 7.9, 100 mM KCl, 2 mM MgCl 2 , 10 µM ZnSO 4 , 10 mM 2 mercaptoethanol, 0.1% NP-40, 10% glycerol, 0.2 mM EDTA and 5 µg/ml sheared salmon sperm DNA. Polyclonal rabbit α-GATA2 (H-116) antibody (Cat. No. sc-9008; Santa Cruz Biotechnology, Inc) (1:100) was added to the nuclear lysates for 20 min before the addition of the probe to show GATA2 as the binding protein. To assess the specificity of the binding, 200-fold excess of each unlabeled probe was used as a competitor. The mixtures were resolved in 6% non-denaturing polyacrylamide gels made in 0.5× TGE buffer (12.5 mM Tris-HCl, pH 8.5, 85 mM glycine and 0.5 mM EDTA), and the electrophoresis was performed at 4 °C. For EMSA-protein blots, the experiment was carried as described above, except that the shifted DNA oligonucleotides-protein complexes were transferred onto nitrocellulose membrane instead of PVDF. The membrane was probed with monoclonal mouse α-GATA2 (CG2-96) antibody (Cat. No. sc-267; Santa Cruz Biotechnology, Inc), and detection was performed as described above.
Determination of genes differentially expressed in the presence of GATA2 mutants. HL-60 cell lines were treated with 100 nM 4HT to turn on wild-type and mutant GATA2 protein expression. After 24 h, gene expression levels were determined by microarray (Supplementary Note).
